Cartalax is the synthetic tripeptide with the amino acid sequence Ala-Glu-Asp (AED). Its molecular weight is 333.29 Da, and its CAS number is 205640-90-0.
Cartalax, the synthetic tripeptide Ala-Glu-Asp (AED), is a short-chain cytogen developed as a tissue-specific bioregulator with pronounced affinity for cells of the cartilage and connective tissue, including chondrocytes and skin fibroblasts. Its exceptionally small size (molecular weight 333.29 Da) enables it to readily cross cellular membranes, penetrate the nucleus without requiring receptor-mediated endocytosis or classical surface signaling pathways, and exert direct effects on nuclear components.
Once inside the cell, AED localizes primarily to the nucleoplasm and nucleolus, where it modulates gene expression through direct interaction with DNA and chromatin structures rather than through conventional second-messenger systems.
The core molecular mechanism of Cartalax involves sequence-specific binding to double-stranded DNA.
Biophysical studies and molecular docking have identified a preferred binding motif for the AED tripeptide: the tetranucleotide ACCT sequence located in the promoter regions of genes critical for cartilage matrix synthesis, cell proliferation, and connective tissue homeostasis.
Binding occurs preferentially in GC-rich regions and leads to local destabilization of the DNA double helix. This interaction sterically hinders repressive chromatin complexes and prevents inhibitory methylation, thereby maintaining promoters in a transcriptionally active, euchromatic state.
In addition to direct DNA interaction, Cartalax modulates chromatin architecture by promoting deheterochromatinization. The tripeptide induces conformational changes that increase the proportion of transcriptionally active euchromatin while reducing condensed heterochromatin, particularly in aging chondrocytes and fibroblasts.
This epigenetic remodeling reactivates genes that are progressively silenced during biological aging, significantly enhancing accessibility of transcription factors to target promoters without altering the underlying DNA sequence.
This process represents a classic example of epigenetic regulation, allowing Cartalax to restore youthful patterns of gene expression in senescent cells.
Key target genes regulated by AED binding in their promoter regions include those involved in:
• Extracellular matrix synthesis — collagen type II (COL2A1), aggrecan, proteoglycans, and SOX9 — leading to enhanced production of cartilage structural components;
• Proliferation markers such as PCNA and Ki67 — supporting chondrocyte division and tissue remodeling;
• Senescence and apoptosis regulators p16, p21, and p53 — whose expression is downregulated under stress conditions;
• Matrix metalloproteinases (MMPs, including MMP-13) and inflammatory enzymes — whose activity is suppressed to help limit cartilage degradation.
Furthermore, Cartalax upregulates genes supporting connective tissue integrity and differentiation in both cartilage and skin fibroblast models, promoting balanced matrix remodeling and cellular resilience.
Under conditions of oxidative, inflammatory, or age-related stress (such as osteoarthritis models, replicative senescence, or cartilage explant cultures), Cartalax finely modulates proliferative and reparative signaling.
It accelerates the transition of chondrocytes into active proliferative phases while preventing excessive apoptosis and senescence. This temporal control helps restore cartilage competence and limits premature cellular aging.
Simultaneously, Cartalax shifts the intracellular balance strongly toward survival, repair, and functional maintenance.
Cartalax demonstrates strong tissue specificity toward cartilage and connective tissue (chondrocytes, fibroblasts), showing minimal activity in unrelated cell types due to the selective distribution of its DNA-binding motifs and chromatin partners in these tissues.
Biophysical studies suggest that Cartalax may also interact with nuclear ribonucleoprotein complexes, stabilizing mRNA transcripts of the upregulated genes and improving translational efficiency.
This multi-level regulation — encompassing direct DNA binding, chromatin deheterochromatinization, proliferation support, matrix synthesis enhancement, and post-transcriptional stabilization — creates a comprehensive molecular program that restores cartilage homeostasis, extracellular matrix balance, and connective tissue resilience.
At the observational level, Cartalax demonstrates pronounced chondroprotective, regenerative, and geroprotective properties that translate its molecular epigenetic actions into measurable improvements in joint function, cartilage integrity, and connective tissue resilience.
It is being investigated in research protocols focused on degenerative joint changes associated with aging, osteoarthritis models, post-traumatic states, and prolonged mechanical stress.
Cartalax significantly supports joint health and cartilage remodeling processes. Experimental observations and preclinical studies consistently demonstrate stimulation of chondrocyte proliferation, increased synthesis of cartilage matrix components (collagen type II and aggrecan), and preservation of cartilage tissue architecture.
In osteoarthritis and age-related cartilage degeneration models, it helps normalize the balance between matrix formation and matrix breakdown, supporting improved structural and functional outcomes.
The peptide exhibits strong anti-inflammatory and tissue-supportive effects in musculoskeletal research settings.
By downregulating degradative enzymes and senescence markers while promoting reparative signaling programs, it helps reduce cartilage breakdown, modulate inflammatory activity, and support recovery following mechanical stress or tissue injury.
Observational reports have noted improvements in joint comfort, flexibility, mobility, and physical performance parameters.
A consistent and well-documented observational finding is support for joint comfort and functional mobility.
In individuals with osteoarthritis-associated or age-related joint changes, adjunctive research use of Cartalax has been associated with reductions in discomfort intensity, improved joint stability, and enhanced quality-of-life measures, often becoming noticeable during structured observation periods.
Cartalax demonstrates clear geroprotective (healthy-aging-supportive) effects on cartilage and connective tissue.
It helps slow biological aging processes by protecting chondrocytes from accumulated oxidative and inflammatory stress, maintaining epigenetic regulation, and supporting extracellular matrix production.
In aging populations, it may help counteract cartilage thinning, reduced elasticity, and progressive joint degeneration.
Continued research exposure has been associated with preservation of musculoskeletal function, joint flexibility, and physical independence over time.
Additional observed benefits include accelerated connective tissue recovery following joint stress or surgical intervention models and broader improvements in connective tissue resilience.
Studies in cartilage explant cultures and animal models confirm increased cartilage area index, elevated proliferation markers (PCNA), and reduced senescence/apoptosis-associated markers (p53).
Cartalax is characterized by excellent tolerability and a favorable safety profile, with minimal adverse effects reported aside from rare individual hypersensitivity reactions.
These observed outcomes are closely linked to its molecular actions on gene expression, chromatin remodeling, extracellular matrix synthesis, anti-senescence pathways, and chondrocyte regeneration, positioning it as a targeted bioregulator for cartilage support, connective tissue resilience, and healthy musculoskeletal aging research.
Read more about cartilage bioregulator peptides and their relationship to connective tissue signaling and extracellular matrix support.
→What Are Bioregulator Peptides?
Learn more about how Cartalax compares to BPC-157 and TB-500 in our detailed regenerative peptide comparison guide exploring cartilage repair, tissue healing, and joint recovery pathways.
Questo articolo è fornito esclusivamente per scopi di ricerca.
Tutte le informazioni fornite da PRG hanno finalità esclusivamente educative e informative.
Buone pratiche per la conservazione dei peptidi
Per mantenere l’affidabilità dei risultati di laboratorio, è essenziale conservare correttamente i peptidi.
Condizioni di conservazione adeguate aiutano a preservarne la stabilità per anni, proteggendoli da contaminazione, ossidazione e degradazione.
Sebbene alcuni peptidi siano più sensibili di altri, seguire queste linee guida permette di prolungarne significativamente la durata e l’integrità strutturale.
Conservazione a breve termine (da giorni a mesi)
Conservare i peptidi al fresco e protetti dalla luce.
Temperature inferiori a 4 °C sono generalmente adeguate.
I peptidi liofilizzati possono rimanere stabili a temperatura ambiente per alcune settimane, ma la refrigerazione è comunque preferibile se non vengono utilizzati subito.
Conservazione a lungo termine (da mesi ad anni)
Conservare i peptidi a –80 °C per la massima stabilità.
Evitare congelatori no-frost: i cicli di sbrinamento possono causare variazioni di temperatura dannose.
Ridurre i cicli di congelamento–scongelamento
Ripetuti cicli accelerano la degradazione.
Suddividere i peptidi in aliquote prima della congelazione.
Prevenire ossidazione e danni da umidità
I peptidi possono essere compromessi dall’esposizione all’aria e all’umidità — in particolare appena rimossi dal congelatore.
Lasciare che la fiala raggiunga la temperatura ambiente prima di aprirla per evitare condensa.
Tenere i contenitori chiusi il più possibile; se disponibile, richiuderli sotto gas secco e inerte (azoto o argon).
Amminoacidi come cisteina (C), metionina (M) e triptofano (W) sono particolarmente sensibili all’ossidazione.
Conservazione dei peptidi in soluzione
I peptidi in soluzione hanno una durata molto più breve rispetto alla forma liofilizzata e sono più soggetti a degradazione batterica.
Se necessario conservarli in soluzione, utilizzare buffer sterili a pH 5–6.
Preparare aliquote monouso per evitare cicli ripetuti di congelamento–scongelamento.
La maggior parte delle soluzioni peptidiche resta stabile fino a 30 giorni a 4 °C, ma le sequenze più sensibili devono rimanere congelate quando non utilizzate.
Contenitori per la conservazione dei peptidi
Scegliere contenitori puliti, integri, chimicamente resistenti e della dimensione adeguata al campione.
Fiale in vetro: offrono chiarezza, durata e resistenza chimica.
Fiale in plastica: polistirene (trasparente ma meno resistente) o polipropilene (traslucido ma resistente ai reagenti).
I peptidi spediti in fiale di plastica possono essere trasferiti in vetro per conservazioni prolungate.
Regenesis Peptide – Suggerimenti rapidi per la conservazione
Conservare i peptidi in un ambiente freddo, asciutto e buio
Evitare cicli ripetuti di congelamento–scongelamento
Minimizzare l’esposizione all’aria
Proteggere dalla luce
Evitare conservazioni prolungate in soluzione
Suddividere in aliquote secondo le esigenze sperimentali
